



## Supplementary Materials


### Supplementary Figures




**Fig. S1** Carbachol (CCh; 5  $\mu\text{mol/L}$ ) suppresses the probability of occurrence of evoked reverberation. **A** Current traces of consecutive trials; the white vertical bar indicates the period from CCh application to wash-out. Typical expanded traces at each stage are shown on the right panel (scale bars, 0.2 nA, 0.1 s). **B** Summary of the effects of CCh (5–10  $\mu\text{mol/L}$ ) on the probability of occurrence of evoked reverberation. A significant reduction occurs after the application of CCh (Before,  $0.25 \pm 0.06$ ; CCh,  $0.013 \pm 0.013$ ; Wash,  $0.20 \pm 0.03$ ;  $n = 4$ ,  $P < 0.05$ , paired  $t$ -test).




**Fig. S2** ACh suppresses polysynaptic currents of evoked reverberation. **A** Example network showing the effects of  $2 \mu\text{mol/L}$  ACh. Left:  $2 \mu\text{mol/L}$  ACh (indicated by the white vertical bar) inhibits reverberation. Right: example traces before (black) and after ACh (blue). Scale bars: upper panel, 0.1 nA, 0.2 s; lower panel, 0.1 nA, 20 ms. **B** Example network showing the effects of  $10 \mu\text{mol/L}$  ACh. Scale bars: upper panel, 1 nA, 0.2 s; lower panel, 1 nA, 20 ms. **C** Example network showing the effects of  $20 \mu\text{mol/L}$  ACh. Scale bars: upper panel, 0.5 nA, 0.5 s; lower panel, 0.5 nA, 50 ms.




**Fig. S3** ACh suppresses the probability of occurrence of evoked reverberation in the presence of a GABA<sub>A</sub> receptor antagonist. **A** ACh (5 μmol/L) suppresses evoked reverberation in the presence of 10 μmol/L bicuculline methiodide (BMI). Left: current traces of consecutive trials; the white vertical bar indicates the period from ACh application to wash-out. Right: typical expanded traces of each stage (scale bars: 0.2 nA, 0.1 s). **B** Summary of the effects of ACh (5–20 μmol/L) in the presence of BMI on the probability of occurrence of evoked reverberation. A significant reduction occurs after the application of ACh (Before:  $0.86 \pm 0.09$ , ACh:  $0.18 \pm 0.18$ , Wash:  $0.52 \pm 0.17$ ,  $n = 5$ ,  $P < 0.05$ , paired  $t$ -test).




**Fig. S4** ACh depolarizes the neuronal membrane potential but does not affect input resistance. **A** Change of membrane potential ( $V_{ACh} - V_{bef}$ ) of glutamatergic neurons after application of ACh. Neuronal membrane potential showed depolarization at all test doses (1  $\mu\text{mol/L}$ :  $4.24 \pm 0.61$ , 5  $\mu\text{mol/L}$ :  $7.73 \pm 0.82$ , 20  $\mu\text{mol/L}$ :  $6.74 \pm 0.74$ ). **B** Change of the membrane potential of GABAergic neurons after application of ACh (1  $\mu\text{mol/L}$ :  $4.46 \pm 0.92$ , 5  $\mu\text{mol/L}$ :  $7.51 \pm 2.10$ , 20  $\mu\text{mol/L}$ :  $5.93 \pm 1.42$ ). **C** The normalized input resistance of glutamatergic neurons does not change after ACh. 1  $\mu\text{mol/L}$ :  $1.04 \pm 0.02$ , 5  $\mu\text{mol/L}$ :  $1.02 \pm 0.04$ , 20  $\mu\text{mol/L}$ :  $1.00 \pm 0.05$ . **D** The normalized input resistance of GABAergic neurons does not change much (<10%) after ACh (1  $\mu\text{mol/L}$ :  $1.09 \pm 0.02$ , 5  $\mu\text{mol/L}$ :  $1.00 \pm 0.04$ , 20  $\mu\text{mol/L}$ :  $0.99 \pm 0.03$ ).



**Fig. S5** ACh receptor antagonists by themselves have no effect on evoked reverberation. **A** Application of mecamylamine (mec), scopolamine (scop), or atropine (atrop) (10  $\mu\text{mol/L}$  each) has no effect on evoked reverberation. White vertical bars indicate periods of drug application. Pseudo-color represents the current amplitude (in nA). **B** Summary of the effects of antagonists on the occurrence of evoked reverberation (normalized to values before drug application. mec:  $0.87 \pm 0.07$ ,  $n = 6$ ,  $P = 0.15$ ; scop:  $0.94 \pm 0.03$ ,  $n = 8$ ,  $P = 0.24$ ; atrop:  $0.92 \pm 0.10$ ,  $n = 7$ ,  $P = 0.48$ ; paired  $t$ -test, drug vs before). **C** Effects of antagonists on the normalized duration of evoked reverberation (mec:  $0.92 \pm 0.04$ ,  $n = 6$ ,  $P = 0.14$ ; scop:  $0.96 \pm 0.03$ ,  $n = 6$ ,  $P = 0.43$ ; atrop:  $1.02 \pm 0.09$ ,  $n = 6$ ,  $P = 0.97$ ; paired  $t$ -test, drug vs before).



**Fig. S6** ACh causes membrane depolarization *via* muscarinic acetylcholine receptor (mAChR) signaling. **A** Example membrane potential recording showing ACh-induced depolarization and restoration by mAChR antagonists. Black, blue, and red lines indicate the application of 5 μmol/L ACh, ACh with 10 μmol/L mecamylamine, and ACh with 10 μmol/L scopolamine, respectively. **B** Summary of membrane potential in 5 μmol/L ACh only, ACh with 10 μmol/L mecamylamine, ACh with 10 μmol/L scopolamine, and washout. Colored data points are the average membrane potential values within corresponding periods recorded from each neuron. Thick black bars indicate the mean membrane potential values of all neurons. Error bars, SEM (Before:  $66.95 \pm 0.53$  mV; ACh:  $60.61 \pm 0.63$  mV,  $P < 0.001$ ; ACh + mec:  $60.67 \pm 0.68$  mV,  $P < 0.001$ ; ACh + scop:  $65.33 \pm 0.61$  mV,  $P < 0.01$ ; Wash:  $66.34 \pm 0.78$  mV,  $P = 0.32$ ;  $n = 10$ , paired *t*-test, drug *vs* before).



**Fig. S7** Illustration of reverberation simulation. **A** Schematic of the neuronal network model. The model simulates the dynamics of the vesicle cycle, synaptic current, and membrane potential, which can modulate network reverberation. **B** Tuning of  $\lambda_{EPSC}$  and  $g_L$  along with increasing ACh concentration in arbitrary units, corresponding to ACh doses from zero (0) to super high (50). **C, D** 2D parameter scan of  $\lambda_{EPSC}$  and  $g_L$ ; colored patches denote the values of the simulated probability of the occurrence of reverberation (**C**) and duration (**D**). In the simulation, EPSC is positively correlated with  $\lambda_{EPSC}$ , and neuronal excitability is negatively correlated with  $g_L$ . As  $\lambda_{EPSC}$  and  $g_L$  decline a pathway that fits the experimental phenomena can be found.

---

## Supplementary Tables

**Table S1** Parameters used in simulations

<b>Parameter</b>	<b>Value</b>	<b>Description</b>
$g_{Ca}$	4.4 mS/cm <sup>2</sup>	Conductance of Ca <sup>2+</sup> channel
$g_K$	8 mS/cm <sup>2</sup>	Conductance of K <sup>+</sup> channel
$g_L$	2 mS/cm <sup>2</sup>	Conductance of leak channel
$V_{Ca}$	120 mV	Equilibrium potential of Ca <sup>2+</sup> channel
$V_K$	-84 mV	Equilibrium potential of K <sup>+</sup> channel
$V_L$	-60 mV	Equilibrium potential of leak channel
$V_1$	-1.2 mV	Turning point of the voltage-dependent function of activation variable $m$
$V_2$	18 mV	Span of the voltage-dependent function of activation variable $m$
$V_3$	2 mV	Turning point of the voltage-dependent function of activation variable $W$
$V_4$	30 mV	Span of the voltage-dependent function of activation variable $W$
$V_E$	0 mV	Equilibrium potential of excitatory synapse
$\theta$	0.04	Reference frequency
$C$	2 $\mu$ F/cm <sup>2</sup>	Membrane capacitance
$\tau_d$	10 ms	Time constant of postsynaptic current decrease
$\tau_r$	61 ms	Time constant of inactive state vesicle transform to recovered state



$\tau$	1250 ms	Time constant of inactive state vesicle transform to super-inactive state
$\tau_s$	10 s	Time constant of super inactive state vesicle transform to recovered state
$\mu$	0.25	Quantity of neurotransmitter release per spike
$I_{app}$	3.5 mA	Background current input in neurons

**Table S2** Variables that affect neuronal excitability

Variables	Value	Derivative
$g_{Ca}$	4.4	-10.5801
$g_K$	8	2.958213
$g_L$	2	70.8396
$V_{Ca}$	120	-0.22268
$V_K$	-84	-0.53797
$V_L$	-60	-3.80167
$V_1$	-1.2	9.449592
$V_2$	19	-14.7947
$V_3$	2	-4.83498
$V_4$	30	7.642972